Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

Harpoon Therapeutics, a clinical-stage immunotherapy company, is set to present exciting interim data from its Phase 1/2 clinical trial at the upcoming European Society of Medical Oncology Congress (ESMO) 2023. The trial is evaluating the efficacy of HPN328, a T cell engager developed by Harpoon, in treating small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN).

HPN328 is derived from Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, which aims to harness the body’s immune system to target and kill tumor cells. By recruiting a patient’s own immune cells, HPN328 shows promising potential in the fight against cancer.

“We are excited to present data from over 70 patients with multiple tumor types in HPN328 monotherapy cohorts, with an emphasis on our ongoing 1 mg priming cohorts with target doses up to 24 mg,” said Dr. Luke Walker, Chief Medical Officer for Harpoon Therapeutics. The presentation will focus on the tolerability and preliminary response data of patients receiving doses above the efficacy threshold of 1.215 mg.

The company is nearing completion of monotherapy dose optimization and has also initiated enrollment in combination cohorts, evaluating HPN328 in combination with atezolizumab. This combination therapy aims to explore the potential of HPN328 in early lines of therapy, providing hope for patients who may benefit from a more comprehensive treatment approach.

The poster presentation at ESMO will be delivered by Dr. Noura Choudhury and will provide valuable insights into the interim results of the Phase 1/2 study. The presentation will take place on Monday, October 23, 2023, from 12:00 to 13:00 CEST in Hall 8. Following the event, the poster will be available on Harpoon’s website, allowing interested parties to access the information and findings.

Harpoon Therapeutics is dedicated to developing innovative immunotherapies that leverage the body’s immune system to combat cancer and other diseases. Their TriTAC platform, which includes HPN328, shows great promise in the treatment of solid tumors and hematologic malignancies. Additionally, Harpoon has developed the ProTriTAC™ platform, which utilizes a prodrug concept to create a therapeutic T cell engager that remains inactive until it reaches the tumor. The company’s extended release TriTAC-XR platform is designed to mitigate cytokine release syndrome, a common side effect of immunotherapies.

With a strong focus on clinical development programs, Harpoon Therapeutics aims to bring novel treatments to patients in need. The company’s dedication to advancing the field of immunotherapy and their commitment to improving patient outcomes make them a key player in the fight against cancer.

For more information about Harpoon Therapeutics and their groundbreaking research, please visit their website at www.harpoontx.com.